Physician profile
Jeffrey B Danzig
NPI 1689653909
$47,637.43
in general payments reported to CMS, 2019-2025
19 companies · $812 in 2025
The $812 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $2,578 · 2021: $3,194 · 2022: $3,879 · 2023: $5,897 · 2024: $4,183 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,775 · Food and Beverage: $2,101 · Travel and Lodging: $15.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,775.00 |
| Food and Beverage | $2,100.89 |
| Travel and Lodging | $15.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45,032.40 | 2019-2024 | Trulance, Xifaxan |
| Celgene Corporation | $416.39 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $399.54 | 2021-2025 | Entyvio, Eohilia |
| Abbvie INC. | $364.79 | 2021-2025 | Rinvoq, Skyrizi, Viberzi |
| Janssen Biotech, INC. | $313.06 | 2019-2025 | Stelara, Tremfya |
| Merck Sharp & Dohme LLC | $202.50 | 2021-2024 | Dificid, Zinplava |
| Lilly USA, LLC | $175.22 | 2024-2025 | Omvoh |
| Pfizer INC. | $174.22 | 2021-2024 | |
| Ferring Pharmaceuticals INC. | $170.26 | 2019-2025 | Rebyota |
| Genzyme Corporation | $97.54 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $69.47 | 2024-2025 | Dupixent |
| Madrigal Pharmaceuticals | $57.82 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $40.96 | 2020-2025 | |
| Ardelyx, INC. | $34.55 | 2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $25.99 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $18.59 | 2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $17.76 | 2025 | Iqirvo |
| Gilead Sciences, INC. | $14.94 | 2025 | |
| Braintree Laboratories, INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Danzig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.